Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study
ConclusionCycles of chemotherapy, sex, uterine cancer, head and neck tumors, testicular cancer, ifosfamide, docetaxel, paclitaxel, pertuzumab, bevacizumab, and dacarbazine increase the risk of dysgeusia.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cancer of the Uterus | Chemotherapy | Docetaxel | Head and Neck Cancer | Statistics | Study | Taxotere | Testicular Cancer